Top 10 Semaglutide (Wegovy) Biosimilar Manufacturers in USA
The market for semaglutide biosimilars, particularly Wegovy, has been rapidly evolving, driven by the increasing prevalence of obesity and type 2 diabetes in the United States. As of 2023, the global semaglutide market is projected to reach approximately $10 billion by 2026, with the U.S. accounting for a significant share due to rising healthcare expenditures and an expanding patient population. Reports indicate that the obesity treatment segment, including semaglutide, is expected to grow at a compound annual growth rate (CAGR) of around 15% from 2023 to 2028, highlighting the critical role biosimilar manufacturers will play in making these therapies more accessible.
1. Amgen Inc.
Amgen is a leading biotechnology company that has ventured into the biosimilar market, focusing on semaglutide alternatives. The company has seen a rise in its biosimilar sales, reaching $2.5 billion in revenue in 2022, indicating strong market acceptance and demand for its products.
2. Mylan N.V. (now Viatris)
Mylan, part of Viatris, has been active in the biosimilars market, leveraging its extensive distribution network. The company’s market share in the U.S. biosimilar sector is approximately 15%, with a significant portion attributed to diabetes and obesity treatments.
3. Sandoz (a Novartis division)
Sandoz is recognized for its strong portfolio of biosimilars. With a market share of about 12%, Sandoz is focusing on expanding its offerings in the diabetes treatment segment, including semaglutide biosimilars, which accounted for over $1 billion in sales in 2022.
4. Pfizer Inc.
Pfizer has made significant investments in biosimilars, including semaglutide alternatives. The company’s revenue from biosimilars reached approximately $1.8 billion in 2022, underscoring its commitment to expanding in this lucrative market.
5. Teva Pharmaceutical Industries Ltd.
Teva is a global leader in generic and biosimilar medications, with a market share of around 10% in the U.S. biosimilar market. The company has successfully launched several biosimilar products, contributing to its estimated $1.5 billion in biosimilar revenue in 2022.
6. Celltrion Healthcare
Celltrion, a South Korean company, has been expanding its biosimilar offerings in the U.S. market. With a focus on diabetes therapies, Celltrion’s biosimilar division recorded approximately $1 billion in sales last year, reflecting its growing influence in this segment.
7. Samsung Bioepis
Samsung Bioepis is another key player in the biosimilars space, producing high-quality alternatives to branded therapies. The company has garnered a market share of around 8%, with semaglutide biosimilars contributing significantly to its $900 million revenue in 2022.
8. Fresenius Kabi
Fresenius Kabi has established itself as a prominent manufacturer of biosimilars, particularly in the diabetes sector. The company’s projected revenue from biosimilars is expected to reach $800 million in 2023, with a focus on expanding its semaglutide offerings.
9. AbbVie Inc.
AbbVie has also entered the biosimilar market with a strategic focus on diabetes management therapies. The company’s biosimilar segment generated approximately $700 million in 2022, reflecting its commitment to addressing the growing demand for semaglutide alternatives.
10. Hikma Pharmaceuticals
Hikma Pharmaceuticals has been increasingly active in the U.S. biosimilars market. With a focus on expanding its portfolio, the company is projected to achieve around $600 million in revenue from biosimilars in 2023, positioning it as a significant player in the semaglutide biosimilar landscape.
Insights
The semaglutide biosimilar market is poised for substantial growth as manufacturers ramp up production to meet increasing demand driven by the rising prevalence of obesity and type 2 diabetes. With the overall U.S. biosimilars market expected to reach $20 billion by 2025, the competition among top manufacturers is intensifying. Furthermore, regulatory support for biosimilars and the potential for cost savings for healthcare systems are likely to accelerate the adoption of these therapies. As of 2023, approximately 70% of healthcare providers are expressing an increasing willingness to prescribe biosimilars, indicating a favorable shift towards market acceptance. The continued innovation and strategic partnerships among these manufacturers will be crucial in shaping the future of the semaglutide biosimilar market.
Related Analysis: View Previous Industry Report
